Anastrozole more effective than tamoxifen in preventing breast cancer recurrence after lumpectomy and radiation therapy in postmenopausal women
16 Jun 2015
Anastrozole is more effective than tamoxifen in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ who have undergone lumpectomy and radiation therapy, a recent phase III randomized trial has shown. Compared to tamoxifen, anastrozole was associated with higher 10-year point estimates for overall survival and disease-free survival (92.1 vs 92.5 percent and 77.9 vs 82.7 percent, respectively). More women who took anastrozole 1 mg/day were free of recurrence of invasive or non-invasive breast cancer than those who took tamoxifen 20 mg/day (93.5 vs 89.2 percent).
Related MIMS Drugs